- Home
- NODK vs OBIO Comparison
NODK vs OBIO Comparison
Compare NODK & OBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NODK
- OBIO
- Stock Information
- Founded
- NODK 1946
- OBIO 2017
- Country
- NODK United States
- OBIO United States
- Employees
- NODK N/A
- OBIO N/A
- Industry
- NODK Property-Casualty Insurers
- OBIO Medicinal Chemicals and Botanical Products
- Sector
- NODK Finance
- OBIO Health Care
- Exchange
- NODK Nasdaq
- OBIO Nasdaq
- Market Cap
- NODK 323.2M
- OBIO 205.0M
- IPO Year
- NODK 2017
- OBIO N/A
- Fundamental
- Price
- NODK $15.55
- OBIO $5.83
- Analyst Decision
- NODK
- OBIO Strong Buy
- Analyst Count
- NODK 0
- OBIO 4
- Target Price
- NODK N/A
- OBIO $15.75
- AVG Volume (30 Days)
- NODK 20.0K
- OBIO 44.2K
- Earning Date
- NODK 11-05-2024
- OBIO 11-11-2024
- Dividend Yield
- NODK N/A
- OBIO N/A
- EPS Growth
- NODK N/A
- OBIO N/A
- EPS
- NODK N/A
- OBIO N/A
- Revenue
- NODK $380,700,000.00
- OBIO $2,079,000.00
- Revenue This Year
- NODK N/A
- OBIO $7.68
- Revenue Next Year
- NODK N/A
- OBIO $110.40
- P/E Ratio
- NODK N/A
- OBIO N/A
- Revenue Growth
- NODK 15.43
- OBIO N/A
- 52 Week Low
- NODK $12.02
- OBIO $4.22
- 52 Week High
- NODK $16.55
- OBIO $11.69
- Technical
- Relative Strength Index (RSI)
- NODK 53.74
- OBIO 60.54
- Support Level
- NODK $15.07
- OBIO $5.20
- Resistance Level
- NODK $15.86
- OBIO $5.99
- Average True Range (ATR)
- NODK 0.31
- OBIO 0.38
- MACD
- NODK 0.00
- OBIO 0.12
- Stochastic Oscillator
- NODK 63.53
- OBIO 87.20
About NODK NI Holdings Inc.
NI Holdings Inc is a stockholding company. The company's operating segments include private passenger auto insurance, non-standard auto insurance, home and farm insurance, crop insurance, commercial insurance, and others. The company operates only in USA.
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.